Bilêl Habacha, Xiao Wei, Florian C Gärtner, Jörg Ellinger, Ralph A Bundschuh, Markus Essler
{"title":"Longterm Survial after Re-challenge with Radiumdichlorid - a Case Report.","authors":"Bilêl Habacha, Xiao Wei, Florian C Gärtner, Jörg Ellinger, Ralph A Bundschuh, Markus Essler","doi":"10.1055/a-1345-3150","DOIUrl":null,"url":null,"abstract":"The life-prolonging effects of Radium223-dichlorid (RaCl2) have been shown in the ALSYMCA trial in 2013 [1] in patients with advanced prostate cancer and dominating bone metastases. Consequently, it was approved by the US Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA). Typical initial treatment consists of 6 cycles RaCl2 given in intervals of 4 weeks. As often relapse of the disease can be observed in the treated patients after some time, soon the repeated application of RaCl2 was discussed and analyzed in prospective trials [2]. While toxicity of repeated application of RaCl2 was found to be acceptable and no major issue in most cases, the outcome was shown to be very variable. Therefore, we want to report on one patient in whom bone metastases of an advanced, castration-resistant prostate carcinoma could be stabilized for nearly two years with repeated treatment with RaCl2.","PeriodicalId":19238,"journal":{"name":"Nuklearmedizin-nuclear Medicine","volume":"60 4","pages":"299-301"},"PeriodicalIF":1.0000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nuklearmedizin-nuclear Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-1345-3150","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/2/18 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
Abstract
The life-prolonging effects of Radium223-dichlorid (RaCl2) have been shown in the ALSYMCA trial in 2013 [1] in patients with advanced prostate cancer and dominating bone metastases. Consequently, it was approved by the US Food and Drug Administration (FDA) as well as the European Medicines Agency (EMA). Typical initial treatment consists of 6 cycles RaCl2 given in intervals of 4 weeks. As often relapse of the disease can be observed in the treated patients after some time, soon the repeated application of RaCl2 was discussed and analyzed in prospective trials [2]. While toxicity of repeated application of RaCl2 was found to be acceptable and no major issue in most cases, the outcome was shown to be very variable. Therefore, we want to report on one patient in whom bone metastases of an advanced, castration-resistant prostate carcinoma could be stabilized for nearly two years with repeated treatment with RaCl2.
期刊介绍：
Als Standes- und Fachorgan (Organ von Deutscher Gesellschaft für Nuklearmedizin (DGN), Österreichischer Gesellschaft für Nuklearmedizin und Molekulare Bildgebung (ÖGN), Schweizerischer Gesellschaft für Nuklearmedizin (SGNM, SSNM)) von hohem wissenschaftlichen Anspruch befasst sich die CME-zertifizierte Nuklearmedizin/ NuclearMedicine mit Diagnostik und Therapie in der Nuklearmedizin und dem Strahlenschutz: Originalien, Übersichtsarbeiten, Referate und Kongressberichte stellen aktuelle Themen der Diagnose und Therapie dar.
Ausführliche Berichte aus den DGN-Arbeitskreisen, Nachrichten aus Forschung und Industrie sowie Beschreibungen innovativer technischer Geräte, Einrichtungen und Systeme runden das Konzept ab.
Die Abstracts der Jahrestagungen dreier europäischer Fachgesellschaften sind Bestandteil der Kongressausgaben.
Nuklearmedizin erscheint regelmäßig mit sechs Ausgaben pro Jahr und richtet sich vor allem an Nuklearmediziner, Radiologen, Strahlentherapeuten, Medizinphysiker und Radiopharmazeuten.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
